ArticleBMC cancer2026
Effectiveness of transarterial drug-loaded microsphere chemoembolization against cholangiocarcinoma combined with obstructive jaundice.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAlthough transarterial chemoembolization (TACE) has been widely used to treat malignant cholangiocarcinoma (CCA), the efficacy of drug-loaded microsphere chemoembolization (DEB-TACE) remains to be comprehensively explored in patients with CCA combined with obstructive jaundice.
methodsIn this single-center retrospective cohort study, patients (n = 101) with CCA combined with obstructive jaundice admitted between January 2021 and December 2022 were treated with DEB-TACE or c-TACE. Initially, the baseline characteristics of the two groups of patients, i.e., DEB-TACE (n = 46) and c-TACE (n = 55), were estimated. Further, the survival time was analyzed using the Kaplan-Meier (KM) method, exploring independent risk factors affecting patients’ survival time by the Cox proportional risk model.
resultsThe DEB-TACE group showed a significantly better imaging efficacy than the c-TACE group, with an objective remission rate (ORR) of 47.8% vs. 0.0% and a disease control rate (DCR) of 95.7% vs. 70.9% (P < 0.001). The survival analysis showed a higher median overall survival (OS) time of 14 months and a 1-year survival rate of 70.7% in the DEB-TACE group than 11 months and 0.0% in the c-TACE group (P < 0.001), respectively. The Cox regression analysis showed the DEB-TACE treatment as an independent protective factor for prolonged OS (HR = 0.072, P < 0.001).
conclusionDespite the low long-term survival rates in both groups, DEB-TACE, as an effective local therapy, could provide an important reference for optimizing the treatment of advanced CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.